Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of CNTO 888 in idiopathic pulmonary fibrosis
2008-001281-86Phase 2Completed
- Sponsor
- Janssen Biotech
- Start
- Sep 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing CNTO 888 with Placebo (2 arms). Primary endpoint: Rate of percent change in FVC through Week 52. Started Sep 2008; status: completed.
02
Drugs
carlumab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2008-001281-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001281-86.